A new study finds that a drug used to prevent migraines may also be effective in reducing rebound headaches caused by overuse of pain medication in people living with chronic migraine.
Medication Overuse Cut Significantly
The study, published on June 26 in Neurology, involved 755 participants with chronic migraine. Atogepant (Qulipta), a calcitonin gene-related peptide (CGRP) receptor antagonist, works by blocking a protein crucial in initiating the migraine process. It received U.S. approval in 2021.Participants taking atogepant twice daily for 12 weeks reported an average of three fewer migraine and headache days per month than the placebo group. Those taking it once daily experienced two fewer migraine and headache days per month.
